UNSPSC 51162733: Prenisteine

This classification denotes a mucolytic agent with the molecular formula C8H15NO2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 99TA452185, chemically known as l-alanine, 3-((3-methyl-2-butenyl)thio)- but more generally known as prenisteine, which bears US NIH Compound Identifier 21359. European Medicines Agency schedules Prenisteine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10028MIG. The term PRENISTEINE is an International Non-Proprietary Name.

UNSPSC 51162733 Prenisteine is a Commodity code under which state and local governments procure pharmaceutical products, specifically naloxone and drug deactivation systems for public health and emergency response programs. Recent solicitations show state and local buyers acquiring naloxone in bulk quantities alongside safe drug deactivation systems for community health initiatives and emergency preparedness, as well as generic multi-source pharmaceuticals and over-the-counter products distributed through cooperative purchasing networks. The issuing bodies include county health departments and state cooperative purchasing alliances administering multi-jurisdiction pharmaceutical procurement. Vendors typically must comply with federal manufacturing standards (current Good Manufacturing Practices, FDA requirements, Drug Supply Chain Security Act), maintain prescribed insurance coverages, and demonstrate E-Verify compliance and drug-free workplace certification.

Recent activity spans Florida and Minnesota. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building, with a response deadline of July 26, 2023. The Minnesota Department of Administration's Office of State Procurement, administering the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), issued RFP S1070000015802 on January 20, 2026 for generic multi-source pharmaceuticals and over-the-counter products to be supplied through authorized wholesalers to participating state and local government facilities in Minnesota and Oregon, with proposals due March 26, 2026 and awarded contracts effective July 1, 2026. MMCAP's evaluation emphasizes price competitiveness at 75 percent weight, with pricing flexibility through flat-fee, net-price, or WAC-minus formats and a required 3 percent administrative fee on all purchases.